|
Market Closed -
Nasdaq
07:00:00 15/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 498.50 USD | +2.74% |
|
-1.41% | +9.96% |
| 09:40pm | Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653 | MT |
| 10/10 | Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children | MT |
| Market Cap | 126B 114B 106B 96.08B 180B 12,024B 182B 1,272B 497B 6,241B 474B 464B 20,071B | P/E 2026 * |
33.3x | P/E 2027 * | 26.8x |
|---|---|---|---|---|---|
| Enterprise Value | 121B 109B 101B 91.87B 172B 11,496B 174B 1,216B 475B 5,967B 454B 444B 19,190B | EV / Sales 2026 * |
9.11x | EV / Sales 2027 * | 8.02x |
| Free-Float |
99.79% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| VRTX | Delayed | |
CBOE
| VRTX | Real-time | |
|
Tradegate
| VX1 | Real-time | |
|
Deutsche Boerse AG
| VX1 | Delayed | |
|
Boerse Muenchen
| VX1 | Real-time | |
|
Borsa Italiana
| 1VRTX | End-of-day quote | |
|
Mexican S.E.
| VRTX * | End-of-day quote | |
|
London S.E.
| 0QZU | Delayed | |
|
Börse Stuttgart
| VX1 | Delayed | |
|
Xetra
| VX1 | Delayed | |
|
Wiener Boerse
| VRTX | End-of-day quote | |
|
CBOE
| 0QZU | Real-time | |
|
CBOE
| Real-time |
Last Transcript: Vertex Pharmaceuticals Incorporated
| 1 day | +2.74% | ||
| 1 week | -1.41% | ||
| Current month | -4.65% | ||
| 1 month | -4.04% | ||
| 3 months | +4.66% | ||
| 6 months | +12.20% | ||
| Current year | +9.96% |
| 1 week | 484.08 |  | 514.9 |
| 1 month | 484.08 | | 529.89 |
| Current year | 412.27 | | 560.25 |
| 1 year | 403.16 | | 560.25 |
| 3 years | 341.9 | | 560.25 |
| 5 years | 177.71 | | 560.25 |
| 10 years | 71.46 | | 560.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 01/04/2020 | |
Charles Wagner
DFI | Director of Finance/CFO | 57 | 10/04/2019 |
Sean Daughtry
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Bruce Sachs
BRD | Director/Board Member | 66 | 01/01/1998 |
Jeffrey Leiden
CHM | Chairman | 70 | 01/05/2012 |
Sangeeta Bhatia
BRD | Director/Board Member | 57 | 18/06/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 28/8/26 | Free | Controller/Auditor | 5,000 | 0.0020% | ||
| 27/8/26 | Don | Director | -6,000 | 0.0024% | ||
| 21/7/26 | Free | General Counsel | 8,251 | 0.0033% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.74% | -1.41% | +20.93% | +34.37% | 126B | |
| +3.62% | +1.68% | +48.80% | +98.41% | 1,077B | |
| +2.13% | -1.76% | +33.04% | +61.88% | 612B | |
| +3.32% | +4.47% | +23.72% | +91.59% | 501B | |
| +3.80% | +3.21% | +73.99% | +41.69% | 364B | |
| +1.24% | +6.15% | +31.78% | +48.48% | 353B | |
| +1.27% | +5.40% | +19.26% | +42.29% | 278B | |
| +2.30% | +5.62% | -0.66% | +14.47% | 251B | |
| +3.21% | +3.15% | +45.01% | +49.99% | 230B | |
| +3.80% | +4.56% | +29.59% | +97.73% | 190B | |
| Average | +1.78% | +1.63% | +32.55% | +58.09% | 398.29B | |
| Weighted average by Cap. | +1.60% | +1.49% | +36.82% | +68.27% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.27B 11.93B 11.13B 10.09B 18.94B 1,263B 19.06B 134B 52.16B 655B 49.81B 48.73B 2,107B | 14.56B 13.1B 12.22B 11.08B 20.79B 1,386B 20.92B 147B 57.27B 719B 54.68B 53.5B 2,314B |
| Net income | 3.88B 3.49B 3.26B 2.95B 5.55B 370B 5.58B 39.11B 15.27B 192B 14.58B 14.27B 617B | 4.89B 4.39B 4.1B 3.72B 6.98B 465B 7.02B 49.21B 19.22B 241B 18.35B 17.95B 776B |
| Net Debt | -5.54B -4.98B -4.65B -4.22B -7.92B -528B -7.97B -55.83B -21.8B -274B -20.82B -20.37B -881B | -9.58B -8.62B -8.04B -7.29B -13.68B -912B -13.77B -96.48B -37.67B -473B -35.97B -35.2B -1,522B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/10/26 | USD 498.50 | +2.74% | 2,090,487 |
| 13/10/26 | USD 485.22 | -4.30% | 1,187,510 |
| 12/10/26 | USD 507.00 | -0.60% | 952,749 |
| 09/10/26 | USD 510.08 | +1.36% | 1,480,861 |
| 08/10/26 | USD 503.25 | -0.47% | 1,487,972 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VRTX Stock
Select your edition
All financial news and data tailored to specific country editions
